Shares of Senseonics Holdings Inc (NYSEAMERICAN:SENS) have received a consensus recommendation of “Buy” from the seven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.00.
Separately, UBS Group initiated coverage on shares of Senseonics in a research report on Tuesday, November 27th. They set a “sell” rating on the stock.
SENS opened at $2.66 on Tuesday. Senseonics has a 12 month low of $2.26 and a 12 month high of $5.29.
A number of large investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Senseonics by 51.9% during the third quarter. BlackRock Inc. now owns 5,790,360 shares of the company’s stock valued at $27,621,000 after acquiring an additional 1,979,353 shares during the last quarter. Vanguard Group Inc raised its stake in shares of Senseonics by 8.7% during the third quarter. Vanguard Group Inc now owns 4,779,370 shares of the company’s stock valued at $22,797,000 after acquiring an additional 382,058 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Senseonics by 8.7% during the third quarter. Vanguard Group Inc. now owns 4,779,370 shares of the company’s stock valued at $22,797,000 after acquiring an additional 382,058 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of Senseonics during the third quarter valued at $14,703,000. Finally, PointState Capital LP bought a new position in shares of Senseonics during the second quarter valued at $10,970,000. 30.66% of the stock is owned by institutional investors and hedge funds.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Further Reading: How Important is Technical Analysis of Stocks
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.